**JULY 15, 2026**

To,
The General Manager
BSE Limited
P.J. Towers, Dalal Street,
Mumbai -400 001

**BSE Scrip: 519242**

**Subject: Outcome of the Board Meeting under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Dear Sir/Madam,

With reference to the above-mentioned subject, we would like to inform you that a meeting of the Board of Directors of Sarda Proteins Limited held on Wednesday, 15th July, 2026, commenced at 04:45 P.M. and concluded at 5:35 P.M. The following business was transacted at the meeting:

1. Considered and approved the Unaudited Standalone Financial Results of the Company (with Limited Review Reports) for the quarter ended June 30, 2026.

2. Approved the shifting of the Registered Office of the Company from B-536-537, Matsya Industrial Area, Alwar – 301030, Rajasthan to 2nd Floor, 2, Sai Collection Building, Bus Stand Road, Police Control Room, Alwar Bus Stand Area, Alwar, Rajasthan – 301001, with effect from 15th July, 2026. The registered office has been shifted within the local limits of the same city, Alwar, Rajasthan.

3. Considered and approved the establishment and commencement of the Corporate Office of the Company with effect from July 15, 2026, at P-212 B, Gate No. 2, Lodhika GIDC, Rajkot, Metoda, Gujarat, India – 360021

4. Considered and approved the appointment of Ms. Minal Surendra Jain holding DIN: 11822395 as an Independent Women Director of the Company for a term of 5 (Five) consecutive years, subject to the approval of the shareholders of the Company.

   Disclosure as required under Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed in given In **Annexure A.**

5. Considered and approved the reconstitution of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee of the Board with immediate effect.

You are requested to take the above information on your record.

Yours faithfully,

**For, Sarda Proteins Limited**

SHIRISH DHIRAJBHAI SAVALIYA

Digitally signed by SHIRISH DHIRAJBHAI SAVALIYA
DN: C=IN, CN=SHIRISH DHIRAJBHAI SAVALIYA, L=JAMNAGAR, O=Personal, ST=GUJARAT, E=CHIRAGSAVALIYA31@GMAIL.COM, postalCode=361160, pseudonym=e8fbf4bd8928178dd8604abe779c32ab, serialNumber=86c8329e60cb8143d8e6fa774e3b103a75206c4bc3a92bb42a972b6305b45cea, street=JAMNAGAR 361160, telephoneNumber=4580e5fb78bc67661a652aaabff95c16dedcafaef6987c8bc88eb7c02f16efcf, title=2528
Reason: I am the author of this document
Location:
Date: 2026.07.15 17:49:14+05'30'
Foxit PDF Reader Version: 2026.1.1

**Mr. Shirish Dhirajlal Savaliya**
**Managing Director,**
**DIN: 08721554**

**Annexure-A**

**Item No. 4: Appointment of Independent Director**

| Sr. No. | Particulars | Details |
|---|---|---|
| 1 | Name of Director | Ms. Minal Surendra Jain |
| 2 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise | Appointment of Ms. Minal Surendra Jain as an Independent Women Director of the Company. |
| 3 | Date of Appointment and Term of Appointment | The Board of Directors, at its Meeting held on 15th July, 2026, has approved the appointment of Ms. Minal Surendra Jain as an Independent Women Director of the Company, not liable to retire by rotation, for a term of 5 (Five) consecutive years commencing from 15th July, 2026, subject to the approval of the shareholders of the Company. |
| 4 | Brief Profile | Ms. Jain is a corporate compliance and governance professional with experience in managing regulatory compliances under the Companies Act, 2013, SEBI Regulations, and Stock Exchange requirements. She has expertise in ROC filings, AIF compliances, investor reporting, corporate governance, regulatory reporting, corporate due diligence, and SEBI SAST disclosures, with a strong focus on ensuring regulatory compliance and governance standards. |
| 5 | Disclosure of relationships between Directors | Ms. Minal Surendra Jain is not related to any Director of the Company. |
| 6 | Information as required pursuant to BSE Circular Ref. No. LIST/COMP/14/2018-19 | Ms. Minal Surendra Jain is not debarred from holding the office of Director by virtue of any Order passed by the Securities and Exchange Board of India (SEBI) or any other statutory authority. |

| | | | | | |
|---|---|---|---|---|---|
| **STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED 30th June, 2026** | | | | | |
| | | **Rs.in Lakhs** | | | |
| **Particulars** | | **Quarter Ended on** | | | **Year Ended** |
| | | **30.06.2026** | **31.03.2026** | **30.06.2025** | **31.03.2026** |
| | | **Un-Audited** | **Audited** | **Un-Audited** | **Audited** |
| I. | Revenue from operations | 1,299.30 | 65.00 | 1,095.46 | 1,615.84 |
| II. | Other Income | 548.10 | 24.31 | 0.08 | 34.85 |
| **III.** | **Total Revenue (I+II)** | **1,847.40** | **89.31** | **1,095.54** | **1,650.69** |
| IV. | Expenses: | | | | |
| | Cost of Material Consumed | - | - | - | |
| | Purchase of Stock -in- Trade | 970.32 | - | 1,128.54 | 1,547.83 |
| | Changes in Inventories (Finished Goods, WIP, Stock-in-Trade) | - | - | - | - |
| | Employee Benefit Expenses | 12.15 | 1.00 | 0.75 | 3.00 |
| | Finance Cost | - | - | - | - |
| | Depreciation and Amoritsation Expenses | - | - | - | 0.05 |
| | Other expenses | 643.63 | 3.83 | 15.59 | 36.01 |
| | **Total Expenses (IV)** | **1,626.10** | **4.83** | **1,144.88** | **1,586.89** |
| V. | Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV) | 221.30 | 84.49 | (49.34) | 63.79 |
| VI. | Exceptional Items | - | - | - | - |
| VII. | Profit/(Loss) before Extraordinary Items and Tax (V-VI) | **221.30** | **84.49** | **(49.34)** | **63.79** |
| VIII. | Extraordinary Items | - | - | - | - |
| IX. | Profit/(Loss) before Tax (V-VI) | **221.30** | **84.49** | **(49.34)** | **63.79** |
| X. | Tax Expense: | | | | |
| | (1) Current Tax | 55.33 | - | - | - |
| | (2) Deferred Tax | - | - | - | - |
| XI. | Profit/(Loss) for the period from Continuing Operations (VII-VIII) | **165.97** | **84.49** | **(49.34)** | **63.79** |
| XII. | Profit/(Loss) from Discontinued Operations | - | - | - | - |
| XIII. | Tax Expenses of Discontinued Operations | - | - | - | - |
| XIV. | Profit/(Loss) from Discontinued Operations (after tax) (X-XI) | - | - | - | - |
| XV. | Profit/(Loss) for the period (IX+XII) | **165.97** | **84.49** | **(49.34)** | **63.79** |
| XVI. | Other Comprehensive Income | | | | |
| | A (i) Items will not be reclassified to Profit or Loss | - | - | - | - |
| | (ii) Income Tax relating to items that will not be reclassified to Profit or Loss | - | - | - | - |
| | B (i) Items will be reclassified to Profit or Loss | - | - | - | - |
| | (ii) Income Tax relating to items that will be reclassified to Profit or Loss | - | - | - | - |

| | | | | | |
|---|---|---|---|---|---|
| **XVII.** | **Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)** | **165.97** | **84.49** | **(49.34)** | **63.79** |
| | Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share) | 89.759 | 89.759 | 17.259 | 89.759 |
| XVIII | Earnings per Equity Share | | | | |
| | (1) Basic | 1.85 | 0.94 | (2.86) | 0.71 |
| | (2) Diluted | 1.85 | 0.94 | (2.86) | 0.71 |
| **Note :-** | | | | | |

1. The above results were approved by Audit Committee in their meeting held on 15th July, 2026 and by Board of Directors in their meeting held on 15th July, 2026.

2. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Cell Products".

3. No Investor Complaints were received during the quarter ended 30-June-2026 nor any pending as on 01-07-2026

4. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

**For, Sarda Proteins Limited**

SHIRISH DHIRAJBHAI SAVALIYA

Digitally signed by SHIRISH DHIRAJBHAI SAVALIYA
DN: C=IN, CN=SHIRISH DHIRAJBHAI SAVALIYA, L=JAMNAGAR, O=Personal, ST=GUJARAT, E=CHIRAGSAVALIYA31@GMAIL.COM, postalCode=361160, pseudonym=e8fbf4bd8928178dd8604abe779c32ab, serialNumber=86c8329e60cb8143d8e6fa774e3b103a75206c4bc3a92bb42a972b6305b45cea, street=JAMNAGAR 361160, telephoneNumber=4580e5fb78bc67661a652aaabff95c16dedcafaef6987c8bc88eb7c02f16efcf, title=2528
Reason: I am the author of this document
Location:
Date: 2026.07.15 17:49:35+05'30'
Foxit PDF Reader Version: 2026.1.1

**Mr. Shirish Dhirajlal Savaliya**
**Managing Director,**
**DIN: 08721554**

**DATE : 15.07.2026**

**Independent Auditor's Review Report on the Unaudited Standalone Financial Results of Sarda Proteins Limited for the Quarter ended on June 30, 2026 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To**
**The Board of Directors of**
**Sarda Proteins Limited**

## 1. Introduction

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Sarda Proteins Limited ("the Company") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

## 2. Management's Responsibility

The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with Indian Accounting Standard (Ind AS) 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

## 3. Auditor's Responsibility

We conducted our review in accordance with SRE 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the ICAI. A review consists primarily of making inquiries of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## 4. Conclusion

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

**For, A H Mandaliya & Associates**
**CHARTERED ACCOUNTANTS**
**FRN: 146705W**

HIREN J MANDALIYA
Digitally signed by HIREN J MANDALIYA
Date: 2026.07.15 17:00:02 +05'30'

**(Hiren J. Mandaliya)**
**Partner**
**Mem. No. :- 140193**
**UDIN :- 26140193FGDSTH5607**

**Date :- 15.07.2026**
**Place :- Ahmedabad**